Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07293351 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
A Phase 1 study of Advanced Renal Cell Carcinoma (RCC), sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 234
- Enrollment target
- 20
- Study locations
NCT07293351 is a Phase 1 study of Advanced Renal Cell Carcinoma (RCC) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 234 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT07293351, a Phase 1 study of Advanced Renal Cell Carcinoma (RCC), is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 234 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Pumitamig
- DRUG Cabozantinib
Study Locations (20)
Other
- Local Institution - 0154 - Buenos Aires
- Local Institution - 0156 - Buenos Aires
- Local Institution - 0003 - Malvern
South Carolina
- Local Institution - 0165 - Charleston
- Carolina Urologic Research Center, LLC - Myrtle Beach
New South Wales
- Local Institution - 0076 - North Ryde
- Local Institution - 0111 - St Leonards
Connecticut
- Local Institution - 0117 - New Haven
District of Columbia
- Local Institution - 0134 - Washington D.C.
Florida
- Local Institution - 0126 - Orlando
Iowa
- Local Institution - 0124 - Iowa City
Maryland
- Local Institution - 0123 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2031-11-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07293351
The ClinicalTrials.gov registry entry for NCT07293351 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Renal Cell Carcinoma (RCC) appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT07293351 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, South Carolina, New South Wales.
Frequently Asked Questions
What is clinical trial NCT07293351 about?
NCT07293351 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)". The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
What is the current status of trial NCT07293351?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 234 participants. The study started on 2026-03-26. Estimated completion is 2031-11-26.
What conditions does trial NCT07293351 study?
This clinical trial studies the following conditions: Advanced Renal Cell Carcinoma (RCC).
What interventions are being tested in trial NCT07293351?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Pumitamig (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT07293351?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07293351 being conducted?
This trial has 20 study locations across Connecticut, District of Columbia, Florida, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.